IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN
EORTC 1740-HNCG
Phase 2 small_molecule active
Quick answer
IMFINZI 50 mg/mL concentrate for solution for infusion., CISPLATIN for Oropharyngeal Squamous Cell Carcinoma is a Phase 2 program (small_molecule) at Cancer Prevention Pharma (Ireland) Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Cancer Prevention Pharma (Ireland) Limited
- Indication
- Oropharyngeal Squamous Cell Carcinoma
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active